From: Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer
Months ± SD (95% Confidence Interval)
Median OS
14 ± 5 (3–25)
Median PFS
14 ± 3 (8–20)
1-year (%)
2-year (%)
OS Rates
55
38
PFS Rates
56
27
Local Control Rates
79
51